Polypeptide

Abstract

The present invention provides a polypeptide inducing the production of an antibody in permucosal administration in the presence of no immunological adjuvant, a composition containing the polypeptide, and use thereof. The present invention solves the above object by providing a polypeptide inserted with a cell attachment motif of a cell adhesive molecule to the peptide which has an amino acid sequence of multiagretope type T cell epitope at the amino terminal side of an inserted linker peptide, and an amino acid sequence of a B cell epitope at the carboxyl terminal side of the inserted linker peptide, a composition containing the polypeptide, and use thereof.

1 . A method for enhancing antigenicity of a B cell epitope, comprising:
 in a polypeptide having antigenicities of the following T cell epitope (i) and B cell epitope (ii), which has been artificially constructed by binding the T cell epitope and the B cell epitope in this order from the N-terminus of the polypeptide,   allowing a linker peptide comprising lysine-lysine to insert between the T cell epitope and the B cell epitope; and   allowing a cell attachment motif of a cell adhesive molecule having an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8 to bind to N- or C-terminus of the T cell epitope;   (i) being a multiagretope type which is restricted by major histocompatibility antigen (MHC) class II haplotypes; and   (ii) being derived from a bacterial protein, virus protein, allergen, toxin, or ovalbumin.   
     
     
         2 . The method of  claim 1 , wherein said B cell epitope is derived from a surface protein antigen of a  Streptococcus mutans  serotype C strain, HIV protein, influenza protein, papilloma virus protein, ovalbumin, amyloid β-peptide, or Japanese cedar pollen allergen.